ATE423316T1 - Verfahren zum nachweis ungenügender bindung von magnesium an zelluläre membranen zum krankheitsnachweis - Google Patents

Verfahren zum nachweis ungenügender bindung von magnesium an zelluläre membranen zum krankheitsnachweis

Info

Publication number
ATE423316T1
ATE423316T1 AT00919293T AT00919293T ATE423316T1 AT E423316 T1 ATE423316 T1 AT E423316T1 AT 00919293 T AT00919293 T AT 00919293T AT 00919293 T AT00919293 T AT 00919293T AT E423316 T1 ATE423316 T1 AT E423316T1
Authority
AT
Austria
Prior art keywords
detecting
magnesium
cellular membranes
disease
insufficient binding
Prior art date
Application number
AT00919293T
Other languages
English (en)
Inventor
Ibert C Wells
Original Assignee
Magnesium Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magnesium Diagnostics Inc filed Critical Magnesium Diagnostics Inc
Application granted granted Critical
Publication of ATE423316T1 publication Critical patent/ATE423316T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00919293T 1999-03-10 2000-03-09 Verfahren zum nachweis ungenügender bindung von magnesium an zelluläre membranen zum krankheitsnachweis ATE423316T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/265,690 US6372440B2 (en) 1999-03-10 1999-03-10 Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses

Publications (1)

Publication Number Publication Date
ATE423316T1 true ATE423316T1 (de) 2009-03-15

Family

ID=23011495

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919293T ATE423316T1 (de) 1999-03-10 2000-03-09 Verfahren zum nachweis ungenügender bindung von magnesium an zelluläre membranen zum krankheitsnachweis

Country Status (7)

Country Link
US (3) US6372440B2 (de)
EP (1) EP1181554B1 (de)
AT (1) ATE423316T1 (de)
AU (1) AU4000400A (de)
CA (1) CA2365666A1 (de)
DE (1) DE60041582D1 (de)
WO (1) WO2000054053A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US20040171093A1 (en) * 1999-03-10 2004-09-02 Wells Ibert C. Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
JP5095391B2 (ja) * 2004-04-20 2012-12-12 スフィンゴテック・ゲーエムベーハー 医療診断におけるタキキニンの前駆体および／またはその断片の使用
US7678444B2 (en) * 2007-12-17 2010-03-16 International Paper Company Thermoformed article made from renewable polymer and heat-resistant polymer
US20090274920A1 (en) * 2008-05-05 2009-11-05 International Paper Company Thermoformed Article Made From Bio-Based Biodegradable Polymer Composition
CN102648234A (zh) * 2009-12-08 2012-08-22 国际纸业公司 由生物基材料的反应性挤出产物制得的热成型制品
WO2015009970A1 (en) 2013-07-18 2015-01-22 Erythron Llc Spectroscopic measurements with parallel array detector
WO2015131151A2 (en) 2014-02-28 2015-09-03 Erythron, Llc Method and apparatus for determining markers of health by analysis of blood
WO2016168090A1 (en) 2015-04-14 2016-10-20 Nueon, Inc. Method and apparatus for determining markers of health by analysis of blood
WO2017165403A1 (en) 2016-03-21 2017-09-28 Nueon Inc. Porous mesh spectrometry methods and apparatus
WO2018085699A1 (en) 2016-11-04 2018-05-11 Nueon Inc. Combination blood lancet and analyzer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894995A (en) * 1972-12-26 1975-07-15 Hoechst Ag Transparent polyamides from an isomeric mixture of norbornanes
US4144244A (en) * 1977-12-27 1979-03-13 Ciba-Geigy Corporation Perfluoroalkyl-iodo norbornane dicarboxylic acids and derivatives thereof
US4331570A (en) * 1980-07-17 1982-05-25 International Flavors & Fragrances Inc. Carboamidoalkyl norbornanes and organoleptic use in perfumes
DE3401949A1 (de) * 1984-01-20 1985-08-01 Bayer Ag, 5090 Leverkusen Norbornan- und norbornencarbonsaeureamide, verfahren zu deren herstellung sowie die verwendung von norbornan- und norbornencarbonsaeureamiden als arzneimittel
US4705897A (en) * 1986-05-05 1987-11-10 Texaco Inc. Process for producing bicyclic diamines
GB8613431D0 (en) 1986-06-03 1986-07-09 Medical Res Council Human tachykinins
US5616562A (en) 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
FR2677362B1 (fr) * 1991-06-04 1995-04-28 Centre Nat Rech Scient Neuropeptides de la famille des tachykinines.
JP3507494B2 (ja) 1992-08-13 2004-03-15 ワーナー−ランバート・コンパニー タキキニン拮抗薬
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
ITFI940009A1 (it) 1994-01-19 1995-07-19 Menarini Farma Ind Antagonisti delle tachichinine, loro preparazione e formulazioni farmaceutiche che li contengono.
JPH10501228A (ja) 1994-06-06 1998-02-03 ワーナー−ランバート・コンパニー タキキニン（ｎｋ▲下１▼）受容体アンタゴニスト
US5491140A (en) 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
US5563133A (en) 1995-02-21 1996-10-08 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5607947A (en) 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
US20040171093A1 (en) * 1999-03-10 2004-09-02 Wells Ibert C. Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states

Also Published As

Publication number Publication date
AU4000400A (en) 2000-09-28
EP1181554A4 (de) 2002-11-06
US20070134738A1 (en) 2007-06-14
EP1181554B1 (de) 2009-02-18
DE60041582D1 (de) 2009-04-02
CA2365666A1 (en) 2000-09-14
WO2000054053A1 (en) 2000-09-14
US20010051345A1 (en) 2001-12-13
US20030077658A1 (en) 2003-04-24
US6372440B2 (en) 2002-04-16
WO2000054053A9 (en) 2001-10-11
EP1181554A1 (de) 2002-02-27

Similar Documents

Publication Publication Date Title
WO2004092199A3 (en) Method for identifying modulators of g protein coupled receptor signaling
ATE321088T1 (de) Polysiloxanpolymere, verfahren zu ihrer herstellung und ihre verwendung
EA200701377A1 (ru) Имплантируемый биоматериал и способ его получения
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
DE60126337D1 (de) Verfahren zum screenen für gpr40-liganden
ATE502058T1 (de) Verfahren zur herstellung von 1,2-dichlorethan
ATE423316T1 (de) Verfahren zum nachweis ungenügender bindung von magnesium an zelluläre membranen zum krankheitsnachweis
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE502005001841D1 (de) Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
IL174195A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
DK1061803T3 (da) Eprosartansammensætninger
WO2006079334A3 (de) Verfahren zu nachweis und quantifizierung von proteinen unter verwendung von farbstoffen auf der basis von polymethinen
WO2010079076A3 (de) Autosomal dominante polyzystische nierenerkrankung (adpkd)
DE69902796D1 (de) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
WO2005018552A3 (en) Heparin binding proteins: sensors for heparin detection
NO20031033D0 (no) Reseptor i EDb-fibronectindomene
WO2004069860A3 (en) Isg15-conjugated proteins
DE60336822D1 (de) Verfahren zur herstellung von kristallinem 1,2-polybutadien
DE60216570D1 (de) Verfahren zum nachweis von alzheimer-krankheit
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands
DE60129933D1 (de) Verfahren zum screening
ATE346957T1 (de) Verfahren zum nachweis von chloralhydrat in dichloressigsäure
WO2005111075A3 (en) CRYSTAL STRUCTURE OF FACTOR VAi AND METHOD FOR IDENTIFYING BLOOD FACTOR Va MODULATORS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties